Ablynx
2001
FOUNDED
M&A
STATUS
401-500
EMPLOYEES
M&A
LATEST DEAL TYPE
$4.56B
LATEST DEAL AMOUNT
Description
Manufacturer of biopharmaceutical products created to offer proteins based therapeutics for treatment of inflammation, hematology, immuno-oncology, oncology and respiratory diseases. The company's biopharmaceutical products comprises of their patented product named, Nanobodies that is a therapeutic proteins based on single-chain antibody fragments that combine the benefits of drugs based on conventional antibodies and small chemical molecules, enabling patients avail various therapeutic and new drugs that can make a clear difference to society.
Website
Formerly Known As
MatchX
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Office
- Technologiepark 21
- 9052 Ghent
- Belgium
+32 09 000 00 00
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Ablynx’s full profile, request a free trial.
Ablynx Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Merger/Acquisition | 19-Jun-2018 | $4.56B | 00000 | 00.000 | Completed | Profitable |
| 13. Merger/Acquisition | 01-Dec-2017 | 00.000 | 00.000 | Cancelled | Profitable | |
| 12. PIPE | 04-Oct-2017 | 00000 | Completed | Profitable | ||
| 11. PIPE | 24-Jan-2017 | 000.00 | 00000 | 00000 | Completed | Generating Revenue |
| 10. Secondary Transaction - Open Market | 03-Nov-2016 | 00000 | Completed | Profitable | ||
| 9. PIPE | 01-Jun-2016 | 000.00 | 00000 | Completed | Profitable | |
| 8. Secondary Transaction - Open Market | 18-Oct-2013 | 00.000 | 00000 | Completed | Generating Revenue | |
| 7. 2PO | 16-Mar-2010 | 000.00 | 00000 | Completed | Generating Revenue | |
| 6. IPO | 07-Nov-2007 | $108M | $196M | Completed | Generating Revenue | |
| 5. Later Stage VC (Series C) | 23-Aug-2006 | $51.2M | $88.2M | Completed | Generating Revenue |
Ablynx Competitors (35)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lixte Biotechnology Holdings | Corporation | East Setauket, NY | 0 | |||
| 00000 | Venture Capital-Backed | Cambridge, United Kingdom | 000 | 00000 | 0000000000 0 | 00000 |
| 000000000 | Venture Capital-Backed | Vancouver, Canada | 00 | 0000 | 00000000000 | 0000 |
| 000000 | Venture Capital-Backed | Lebanon, NH | 000 | 000.00 | 00000000000 | 000.00 |
| 00000 000000 | Venture Capital-Backed | New York, NY | 0000 | 0000000000 0 | 0000 |
Ablynx Former Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Abingworth Management | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Alta Partners | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Fidelity Management & Research | Asset Manager | Minority | 000 0000 | 000000 0 | ||
| Foresite Capital Management | Growth/Expansion | Minority | 000 0000 | 000000 0 | ||
| Gilde Healthcare Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
Ablynx Executive Team (17)
9 Former Executives
You’re viewing 5 of 17 executives. Get the full list »Ablynx Board Members (9)
5 Former Board Members
You’re viewing 4 of 9 board members. Get the full list »